This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (66)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Roger D. Blevins, PharmD; Nicholas Z. Kerin, MD; David Benaderet, MD; Howard Frumin, MD; Kathy Faitel; Regina Jarandilla; Melvyn Rubenfire, MD

Arch Intern Med. 1987;147(8):1401-1404.

Abstract
• Thirty-eight patients were studied to evaluate amiodarone hydrochloride in the treatment of refractory atrial fibrillation. Among them were 25 with sustained atrial fibrillation and 13 with paroxysmal atrial fibrillation. All patients were symptomatic and refractory to therapeutic doses of at least two conventional drug trials, and patients with atrial fibrillation had relapsed from electroversion. Amiodarone hydrochloride was administered in doses of 5 mg/kg intravenously, then 600 to 800 mg/d for seven to ten days, followed by 200 to 400 mg/d. Holter recordings were obtained every one to three months. The effect of amiodarone on the ventricular rate during sustained atrial fibrillation was evaluated in 18 patients and decreased from 99/min (range, 72/min to 143/min) at baseline to 75/min (range, 60/min to 102/min) at follow-up before conversion. Conversion to normal sinus rhythm occurred in 19 patients (76%), including 11 with and eight without directcurrent cardioversion. During long-term treatment, sinus rhythm was sustained on an average of 16 months (range, three to 27 months) in 20 patients (53%). This included 11 of 25 patients with sustained atrial fibrillation and nine of 13 patients with paroxysmal atrial fibrillation, with only four of these patients relapsing. Four patients (11%) developed intolerable side effects, but no serious toxic effects were encountered, perhaps because of the relatively low doses of amiodarone hydrochloride that were used (average, 232 ±80 mg/d). Amiodarone is a safe and effective alternative to standard therapy in patients with refractory sustained or paroxysmal atrial fibrillation.

(Arch Intern Med 1987;147:1401-1404)

Author Affiliations
From the Section of Cardiovascular Diseases, Department of Medicine, Sinai Hospital of Detroit (Drs Blevins, Kerin, Benaderet, Frumin, and Rubenfire and Mss Faitel and Jarandilla); and Wayne State University, Detroit (Drs Blevins, Kerin, Frumin, and Rubenfire).

Footnotes
Accepted for publication May 7, 1987.

Presented in part at the 58th Annual Scientific Session of the American Heart Association, Washington, DC, Nov 12, 1985.

Reprint requests to Department of Medicine, Sinai Hospital of Detroit, 6767 W Outer Dr, Detroit, MI 48235 (Dr Kerin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Writing Committee Members et al.
Europace 2006;8:651-745.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
J Am Coll Cardiol 2006;48:e149-e246.
FULL TEXT  

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Fuster et al.
Circulation 2006;114:e257-e354.
FULL TEXT  

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur Heart J 2001;22:1852-1923.
 

ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
Fuster et al.
J Am Coll Cardiol 2001;38:1266-1266.
FULL TEXT  

Electrophysiologic and Antiarrhythmic Effects of the New Class III Antiarrhythmic Drug KCB-328 in Experimental Canine Atrial Flutter
Rahme et al.
J CARDIOVASC PHARMACOL THER 2001;6:297-306.
ABSTRACT  

Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting
Lee et al.
Ann. Thorac. Surg. 2000;70:157-161.
ABSTRACT | FULL TEXT  

Electrophysiological and Antiarrhythmic Effects of the Atrial Selective 5-HT4 Receptor Antagonist RS-100302 in Experimental Atrial Flutter and Fibrillation
Rahme et al.
Circulation 1999;100:2010-2017.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation
Catherwood et al.
ANN INTERN MED 1999;130:625-636.
ABSTRACT | FULL TEXT  

Intravenous Amiodarone in the Management of Atrial Fibrillation
Reiffel
J CARDIOVASC PHARMACOL THER 1999;4:199-204.
ABSTRACT  

Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)
Deedwania et al.
Circulation 1998;98:2574-2579.
ABSTRACT | FULL TEXT  

Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Li and Hohnloser
J CARDIOVASC PHARMACOL THER 1998;3:185-194.
ABSTRACT  

Atrial Fibrillation: Defining Some Unanswered Questions
Singh and Lopez
J CARDIOVASC PHARMACOL THER 1998;3:195-199.
 

Preoperative Amiodarone as Prophylaxis against Atrial Fibrillation after Heart Surgery
Daoud et al.
NEJM 1997;337:1785-1791.
ABSTRACT | FULL TEXT  

The Efficacy of Intravenous Amiodarone for the Conversion of Chronic Atrial Fibrillation: Amiodarone vs Quinidine for Conversion of Atrial Fibrillation
Kerin et al.
Arch Intern Med 1996;156:49-53.
ABSTRACT  

Treatment of Resistant Atrial Fibrillation: A Meta-analysis Comparing Amiodarone and Flecainide
Zarembski et al.
Arch Intern Med 1995;155:1885-1891.
ABSTRACT  

Antiarrhythmic Prophylaxis vs Warfarin Anticoagulation to Prevent Thromboembolic Events Among Patients With Atrial Fibrillation: A Decision Analysis
Middlekauff et al.
Arch Intern Med 1995;155:913-920.
ABSTRACT  

Low-Dose Amiodarone for Maintenance of Sinus Rhythm After Cardioversion of Atrial Fibrillation or Flutter
Gosselink et al.
JAMA 1992;267:3289-3293.
ABSTRACT  

Low-Dose Amiodarone for Atrial Fibrillation: Time for a Prospective Study?
Middlekauff et al.
ANN INTERN MED 1992;116:1017-1020.
ABSTRACT  

Frontiers in Surgery: A Perspective
Pierce and Sobel
JAMA 1991;266:1990-1992.
ABSTRACT